Dear Editor,
We report a rare clinical case of Sertoli-Leydig cell tumor (SLCT) culminating in uterine inversion. These tumors represent less than 0.2% of primary ovarian tumors and present diagnostic and therapeutic challenges due to their rarity, heterogeneous clinical presentation, and risk of malignancy. The definitive diagnosis is histopathological. First-line treatment is surgical. Adjuvant chemotherapy and radiotherapy may be indicated. The prognosis depends on the histological subtype and disease stage. Non-puerperal uterine inversion, with multifactorial pathophysiology and morbidity, is a rare gynecological complication. Aggressive behavior and size of the SLCT may contribute to uterine inversion.

Click here for the full paper.